• Pamela Carroll, Ph.D.

    SVP, Immuno-oncology

    Pamela Carroll, Ph.D. joined Genocea in 2016 to lead immuno-oncology efforts.  She brings expertise in cancer biology and immuno-oncology to the development and strategic direction of Genocea’s oncology programs. Her previous positions include vice president of oncology discovery at Roche Pharma Research and Early Development, vice president of Janssen oncology at Johnson and Johnson Innovation, and founding Head of Research at the Belfer Institute for Applied Cancer Science at Dana Farber Cancer Institute.  Dr. Carroll developed her drug discovery experience at Bristol-Myers Squibb in applied genomics and Merck Research Laboratories in oncology. Dr. Carroll earned her B.A. in biology at St. Michael’s College in Vermont, a doctorate in cellular biology at Stony Brook University, and a post-doctorate fellowship at Stanford University.

    • Chip Clark

      President and Chief Executive Officer

      William Clark has served as our President and Chief Executive Officer since February 2011. Previously he served as our Chief Business Officer from August 2010 to February 2011. Mr. Clark has served on our board of directors since February 2011. Prior to joining our Company, he served as Chief Business Officer at Vanda Pharmaceuticals, Inc. ("Vanda"), a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company’s strategic and business development activities, and played a central role in raising more than $220 million in multiple public and private financings. Prior to Vanda, Mr. Clark was a principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline). Mr. Clark holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

      • Jessica Baker Flechtner Ph.D.

        Chief Scientific Officer

        Jessica Baker Flechtner, Ph.D. joined Genocea in 2007, soon after the company was founded, and currently serves as the Chief Scientific Officer. Dr. Flechtner is a pioneer in the development of novel vaccines directed toward T cell immunity, and has more than 20 years of experience in immunology, infectious disease, cancer, and vaccine development.  She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against infectious diseases and other indications. Prior to joining Genocea, Dr. Flechtner developed vaccines and immunotherapies for cancer, infectious disease, autoimmunity and allergy in several companies including Mojave Therapeutics and Antigenics Inc. (now Agenus). She is an inventor on ten pending and four issued patents and has multiple peer-reviewed scientific publications. Dr. Flechtner performed her post-doctoral work at the Dana Farber Cancer Institute and Harvard Medical School. She holds a Ph.D. in Cellular Immunology and a B.S. in Animal Science from Cornell University, and is a member of the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, and American Society for Microbiology.

        • Eric S. Hoffman

          Chief Business Officer

          Prior to joining Genocea, Eric was vice president of corporate and business development, program management and commercial operations at Idenix Pharmaceuticals, Inc. before its acquisition by Merck in August 2014. Eric also held roles in investor relations and corporate communications whilst at Idenix. Prior to Idenix, Eric spent four years at Biogen Idec in investor relations and business development roles and spent six years on Wall Street as an equity research analyst at J.P. Morgan, Schwab Soundview Capital Markets and Bear Stearns. Before starting on Wall Street in 2001, he was a post-doctoral research scientist in the Department of Immunobiology at Guy's Hospital in London, studying T cell development. He has authored several book chapters and peer-reviewed papers, including in Cell,Immunity, and Genes & Development. He holds a Ph.D. in Immunobiology from Yale University and a B.S. in Biology from Trinity University.

          • Narinder Singh

            SVP, Pharmaceutical Sciences and Manufacturing

            Narinder Singh joined Genocea in March 2018, and currently serves as Senior Vice President, Pharmaceutical Sciences and Manufacturing. Mr. Singh has more than 20 years of experience in process development, scale-up, technical operations and manufacturing supply chain of biopharmaceuticals. Prior to joining Genocea, Mr. Singh was Vice President of Drug Product Development and Manufacturing at Momenta Pharmaceuticals where he built an integrated drug product group to support Momenta’s expanding portfolio of biosimilars and novel biologics pipeline. Prior to Momenta, Mr. Singh was at Amgen where he played a key role in development of Amgen’s biologics based pipeline and commercial drug products with a strong focus on process development, commercialization, manufacturing, and new technology development.  Mr. Singh holds a B.Tech/M.Tech in Biochemical Engineering and Biotechnology from Indian Institute of Technology, Delhi, an M.S. in Chemical Engineering from University of Houston, and an M.B.A. from UCLA Anderson School of Management.